Semaglutide Cuts BMI in Children with Obesity, Phase 3 Trial Finds

Semaglutide Cuts BMI in Children with Obesity, Phase 3 Trial Finds
AI-generated illustration

A large randomised trial has found that the weight-loss drug semaglutide reduced body mass index (BMI) much more than a dummy treatment in children aged six to eleven with obesity.

Results from the STEP Young trial, presented at ObesityWeek, show that semaglutide — the active ingredient in medicines such as Ozempic and Wegovy — produced a meaningfully greater fall in BMI compared with placebo in a phase 3, double-blind, randomised trial. The study enrolled 165 children in that age group, all living with obesity.

The trial design — phase 3, double-blind, randomised — sits at the top of the evidence hierarchy for clinical research. In plain terms: neither the children nor the clinicians administering the treatment knew who was receiving the drug and who was receiving the dummy injection, which reduces the risk of bias skewing the results. The findings were published in full in the New England Journal of Medicine.

Semaglutide works by mimicking a gut hormone (glucagon-like peptide-1, or GLP-1) that signals fullness to the brain and slows the emptying of the stomach. It is already licensed in the UK for adults with obesity, but its use in younger children remains under regulatory review.

The NEJM posted the trial results on social media ahead of the full publication.

The published trial reported no new safety concerns, with children receiving maximum doses of 1.7 mg or 2.4 mg. Clinicians and families should await formal guidance from the NHS and MHRA before drawing conclusions about treatment options for children.

Source: @NEJM